More Stories

Informist, Wednesday, May 13, 2026

 

Please click here to read all liners published on this story

--Cipla Jan-Mar consol net profit INR 5.55 bln 
--Analysts saw Cipla Jan-Mar consol net profit at INR 7.11 bln 
--Cipla Jan-Mar consol revenue INR 65.41 bln 
--Analysts saw Cipla Jan-Mar consol revenue at INR 66.50 bln 
--Cipla Jan-Mar consol net profit INR 5.55 bln vs INR 12.22 bln year ago 
--Cipla to pay INR 13 per share final dividend 
--Cipla Jan-Mar consol revenue INR 65.41 bln vs INR 67.30 bln year ago 
--Cipla final dividend record date Jun 5 
--Cipla FY26 consol net profit INR 38.79 bln vs INR 52.73 bln year ago 
--Cipla FY26 consol revenue INR 281.63 bln vs INR 275.48 bln year ago 
--Cipla Jan-Mar consol expenses INR 59.82 bln vs INR 55.15 bln year ago 
--Cipla Jan-Mar consol EBITDA INR 9.97 bln vs INR 15.38 bln year ago 
--Cipla Jan-Mar India sales INR 30.07 bln, up 15% on year 
--Cipla Jan-Mar consol EBITDA margin 15.2% vs 22.8% year ago 
--Cipla Jan-Mar North America sales INR 14.14 bln, down 26% on year 
--Cipla Jan-Mar One Africa sales INR 12.36 bln, up 21% on year 
--Cipla Jan-Mar consol R&D expense INR 5.09 bln, 7.8% of sales 
--Cipla Jan-Mar Emerging Markets, Europe sales INR 8.19 bln, dn 9% on year 
--Cipla Jan-Mar North America sales $155 mln vs $221 mln year ago 
--Cipla: Plan to file 4 assets in 24 months under repiratory pipeline 
--Cipla: Plan to file 3 assets in 1-2 yrs under peptide, complex generics 
--Cipla: To launch select pdts under peptide, complex generics in FY27, FY28 

 

By Gunjan Rajput

 

NEW DELHI –  Cipla Ltd. reported a sharp year-on-year fall in its consolidated net profit for the March quarter, marking the second straight quarter of decline in profit, as higher expenses and weak sales affected its earnings performance. Revenue also fell marginally on year after 14 quarters of growth, and both profit and revenue missed analysts' expectations.

 

The drugmaker posted a consolidated net profit of INR 5.55 billion, down nearly 55% on year, for the reporting quarter, and sharply lower than INR 12.22 billion a year ago and below analysts' estimate of INR 7.11 billion. The company's revenue from operations fell nearly 3% on year to INR 65.41 billion, missing analysts' estimate of INR 66.50 billion.

 

The company's total expenses for the March quarter rose over 8% on year to INR 59.82 billion, sharply denting profits. The increase was largely driven by higher employee benefits expense and purchase of stock-in-trade. Employee benefit expenses rose about 15% on year to INR 14.14 billion, while other expenses increased over 6% on year to INR 18.81 billion. Cost of raw material consumed fell over 1% on year to INR 13.82 billion, but expenses related to the purchase of stock-in-trade were up over 25% on year to INR 12.85 billion.

The company's consolidated earnings before interest, tax, depreciation and amortisation fell to INR 9.97 billion in the March quarter from INR 15.38 billion a year ago. The consolidated EBITDA margin narrowed to 15.2% from 22.8% in Jan-Mar of 2025. Growth in Cipla's India and One Africa businesses was offset by a sharp decline in North America sales in Jan-Mar, leading to a contraction in profitability. The decline in the company's sales in its emerging markets and European businesses also weighed on profitability.

 

Cipla's India business revenue rose 15% on year to INR 30.07 billion. "India business grew at a robust 15% YoY (year-on-year) with all 3 segments delivering double-digit growth during the quarter. The branded prescription business sustained growth momentum in key chronic therapies, trade generics continued its steady growth and anchor brands...continued to grow bigger," the company said in its investor presentation.

 

The company's North America sales fell 26% on year to INR 14.14 billion, or $155 million, from $221 million a year ago. Revenue from the One Africa business rose 21% to INR 12.36 billion, while sales in emerging markets and Europe declined 9% to INR 8.19 billion amid geopolitical uncertainties in Jan-Mar. The company incurred research and development expenses of INR 5.09 billion during the quarter, accounting for 7.8% of sales in the reporting quarter, driven by product filings and development efforts.

 

For 2025-26 (Apr-Mar), the company reported a consolidated net profit of INR 38.79 billion, down over 26% from INR 52.73 billion in the previous year, while revenue rose marginally to INR 281.63 billion from INR 275.48 billion. During FY26, the drugmaker launched products such as Voltido Trio Ciphaler, Huena, Zemdri, and Empacip, as per the investor presentation.

 

Among key brands, Dytor crossed INR 6.50 billion in sales, while Foracort surpassed INR 10 billion sales in the Indian pharmaceutical market, according to the company's investor presentation. The company said its India business continued to see double-digit growth in chronic therapies, including respiratory, urology, anti-diabetes and cardiac segments.

 

Cipla plans to strengthen its specialty portfolio with filings in respiratory, peptide and complex generic segments over the next two years, while targeting select launches in the peptide and complex generics space in FY28. The company said it plans to file four assets under its respiratory pipeline in the next 24 months. It also aims to file three assets in peptide and complex generics over the next one to two years. Select product launches in the peptide and complex generics segment are planned for FY28. 

 

Cipla aims to maintain strategic focus in its North America business amid the near-term challenges in the markets in that region, as per the investor presentation. The One Africa business will see a scaling-up, the company said in the presentation.
 

The board of the company recommended a final dividend of INR 13 per share for FY26. The record date for the dividend has been fixed as Jun. 5. The company announced its March quarter results during market hours. At 1408 IST, shares of the company traded at INR 1,347.20 on the National Stock Exchange, up over 4% from the previous close.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Tanima Banerjee

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel+91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.